Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

NeuroBo Pharmaceuticals, Inc. NRBO NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

NeuroBo Pharmaceuticals, Inc. (NRBO) is a Biotechnology company in the Healthcare sector, currently trading at $2.36. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Net income is $13M (loss), growing at -19.2%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $210,000 against $5M equity (Debt-to-Equity (D/E) ratio 0.04, conservative). Current ratio is 1.93 (strong liquidity). Debt-to-assets is 1.9%. Total assets: $11M.

Analyst outlook: 2 / 2 analysts rate NRBO as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

NRBO SharesGrow Score Overview

61/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NRBO

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
NRBO: +0%/yr revenue is, -19.2%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet NRBO: Debt-to-Equity (D/E) ratio 0.04 (conservative), Current ratio is 1.93 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
NRBO: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 2 / 2 analysts rate NRBO as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
Market Cap$20.33M
Beta (1Y)-0.28
Share Statistics
EPS (TTM)-7.35
Shares Outstanding$1.77B
IPO Date2016-08-05
Employees8
CEOHyung-Heon Kim
Financial Highlights & Ratios
EBITDA$-13.71M
Net Income$-12.97M
Operating Income$-13.71M
Total Cash$10.28M
Total Debt$210K
Net Debt$-10.07M
Total Assets$11.12M
Price / Earnings (P/E)-0.3
Analyst Forecast
Rating ConsensusBuy
Analysts Covering2
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeNASDAQ Capital Marke
CurrencyUSD
ISINUS64132R4048

Price Chart

Track all markets on TradingView
NRBO
NeuroBo Pharmaceuticals, Inc. ↗  ·  NASDAQ Capital Marke
Healthcare • Biotechnology

People Also View

ATNF
ATNF
180 Life Sciences Corp.
$7.04
-7.49%
 ZURA
ZURA
Zura Bio Limited
$5.72
+0.70%
 ALLR
ALLR
Allarity Therapeutics, Inc.
$1.19
-0.76%
 PHIO
PHIO
Phio Pharmaceuticals Corp.
$1.29
+4.03%
 KPRX
KPRX
Kiora Pharmaceuticals, Inc.
$2.44
-0.33%
 SONN
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
-59.35%
 REVB
REVB
Revelation Biosciences, Inc.
$1.20
+0.84%
 HILS
HILS
Hillstream BioPharma, Inc.
$0.24
+5.66%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message